Celularity (CELU) Cash from Investing Activities (2019 - 2024)
Celularity (CELU) posted quarterly Cash from Investing Activities of -$1.6 million for Q4 2024, down 174.31% year-over-year from $2.1 million in Q1 2024, and down 174.21% quarter-over-quarter from $2.1 million in Q2 2024.
Celularity (CELU) Cash from Investing Activities (2019 - 2024) Analysis & Trends
Celularity (CELU) has reported Cash from Investing Activities for 6 consecutive years, with -$1.6 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 174.31% year-over-year to -$1.6 million; the TTM figure through Dec 2024 stood at $514000.0 (up 112.7% YoY), while the FY2024 annual figure was $514000.0, up 112.7% from the prior year.
- Cash from Investing Activities slipped to -$1.6 million in Q4 2024 per CELU's latest filing, from $2.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $2.1 million in Q2 2024 and bottomed at -$9.4 million in Q4 2020.
- Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of -$1.1 million in 2021.
- Annual changes were most pronounced in 2020 — Cash from Investing Activities tumbled 8179.31% — and 2024, when it jumped 7016.13%.
- Celularity's Cash from Investing Activities stood at -$9.4 million in 2020, then surged by 75.43% to -$2.3 million in 2021, then jumped by 66.17% to -$779000.0 in 2022, then advanced by 25.55% to -$580000.0 in 2023, then slumped by 174.31% to -$1.6 million in 2024.
- Business Quant data shows CELU's Cash from Investing Activities at -$1.6 million in Q4 2024, $2.1 million in Q2 2024, and -$39000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.59 Mn |
| Dec 31, 2024 | -1.59 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Mar 31, 2024 | -39,000.00 |
| Mar 31, 2024 | -39,000.00 |
| Dec 31, 2023 | -580,000.00 |
| Dec 31, 2023 | -580,000.00 |
| Sep 30, 2023 | -228,000.00 |
| Sep 30, 2023 | -228,000.00 |
| Jun 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -31,000.00 |
| Mar 31, 2023 | -3.21 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Dec 31, 2022 | -779,000.00 |
| Dec 31, 2022 | -779,000.00 |
| Sep 30, 2022 | -1.56 Mn |
| Sep 30, 2022 | -1.56 Mn |
| Jun 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -1.44 Mn |